Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF295 antisense RNA 1 (ZNF295-AS1)
- Target
- ZNF295-AS1
- Molecular classification
- Long noncoding RNA (lncRNA), Antisense RNA, Not a protein, Not a receptor, Not an enzyme, Not a classical therapeutic target
01
Overview
ZNF295 antisense RNA 1 (ZNF295-AS1) is a long noncoding RNA gene located on chromosome 21q22.3. It functions primarily as an antisense RNA regulating gene expression, especially interacting with the ZNF295 gene. Recent literature highlights its role in regulating autophagy in endothelial cells, implicating it in the development and progression of atherosclerosis. It is associated through genetic studies with diseases including lung cancer susceptibility and autism spectrum disorder[1][3][9]. ZNF295-AS1 is not translated into protein and is classified as a non-protein coding RNA gene[2][4]. There are no drugs or therapeutic agents targeting ZNF295-AS1, and its use as a biomarker or therapeutic target remains investigational.
- Other names
- PRED87C21orf121NCRNA00318ZNF295 antisense RNA 1ZNF295-AS1
02
Mechanism of action
Not applicable for direct drug targeting. Mechanistically, ZNF295-AS1 has been described to inhibit autophagy via the ZNF295-AS1/miR-508-5p/ATG7 pathway in atherosclerosis models.
03
Biological functions
Regulation of autophagy (especially in endothelial cells)Gene expression regulation (as antisense RNA)
04
Disease associations
Atherosclerosis (through regulation of endothelial cell autophagy)Cancer (associations include lung cancer susceptibility)Autism spectrum disorderOther disease associations in GWAS databases exist, but role is yet incompletely characterized
05
Biomarkers
Potential marker for atherosclerosis progression or endothelial cell autophagy dysregulation (preclinical evidence only)Possible cancer biomarker (gene is associated with cancer susceptibility in datasets)No clinically validated biomarkers associated with this target
Beyond the preview
Go deeper on ZNF295 antisense RNA 1 (ZNF295-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZNF295 antisense RNA 1 (ZNF295-AS1).